(Q27853128)

English

Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors.

scientific article

In more languages

Statements

scholarly article

2 references

13 November 2016

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25672916%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25672916%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25672916%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Jennifer L Winkelmann

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25672916%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Mario E Lacouture

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25672916%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

11

object named as

Alexia Iasonos

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25672916%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1

object named as

David M Hyman

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25672916%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

Alexandra E Snyder

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25672916%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Richard D Carvajal

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25672916%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

John F Gerecitano

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25672916%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Martin H Voss

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25672916%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Alan L Ho

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25672916%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Megan A Stasi

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25672916%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Kelsey R Monson

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25672916%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

David R Spriggs

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25672916%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Philip Bialer

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25672916%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Jerrold B Teitcher

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25672916%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Nora Katabi

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25672916%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Matthew G Fury

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25672916%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

publication date

12 February 2015

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25672916%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25672916%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

75

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25672916%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25672916%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

747-755

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25672916%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

https://scigraph.springernature.com/pub.10.1007/s00280-015-2693-z

0 references

The PI3K pathway as drug target in human cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2693-Z

21 January 2018

PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2693-Z

21 January 2018

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2693-Z

21 January 2018

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2693-Z

21 January 2018

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2693-Z

21 January 2018

The PHQ-9: validity of a brief depression severity measure

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2693-Z

21 January 2018

A brief measure for assessing generalized anxiety disorder: the GAD-7.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2693-Z

21 January 2018

Comparative genomic analysis of primary versus metastatic colorectal carcinomas.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2693-Z

21 January 2018

Genomic and biological characterization of exon 4 KRAS mutations in human cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2693-Z

21 January 2018

Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2693-Z

21 January 2018

Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2693-Z

21 January 2018

Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2693-Z

21 January 2018

Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2693-Z

21 January 2018

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2693-Z

21 January 2018

Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179).

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2693-Z

21 January 2018

A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2693-Z

21 January 2018

Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2693-Z

21 January 2018

A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC).

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2693-Z

21 January 2018

A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2693-Z

21 January 2018

Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2693-Z

21 January 2018

Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and ro

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2693-Z

21 January 2018

PTEN-deficient cancers depend on PIK3CB.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2693-Z

21 January 2018

Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2693-Z

21 January 2018

Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation

1 reference

https://pubmed.ncbi.nlm.nih.gov/25672916

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25672916

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling

1 reference

https://pubmed.ncbi.nlm.nih.gov/25672916

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25672916

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00280-015-2693-Z

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25672916%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25672916%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

2 references

13 November 2016

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25672916%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27853128&oldid=1753047396"